Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Learn more about our company
Visions and Values
Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg
This approval reinforces Sandoz leadership in complex, differentiated generic products.
October 02, 2015
Sandoz, a Novartis company and the global leader in biosimilars, announced today that the FDA has accepted its Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept)....
Our people are our greatest resource. We are always looking for new colleagues to share in our commitment to make the world a healthier place.Learn more about careers at Sandoz
Watch our videos to discover more about the world of Sandoz and the generics market.Visit our video gallery to watch the latest episode